Cash Flow Statement

Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

DiaMedica Therapeutics (DMAC) Capital Expenditures (2018 - 2019)

DiaMedica Therapeutics' Capital Expenditures history spans 2 years, with the latest figure at $14000.0 for Q4 2019.

For Q4 2019, Capital Expenditures rose 207.69% year-over-year to $14000.0; the TTM value through Dec 2019 reached $22000.0, down 56.0%, while the annual FY2025 figure was $40000.0, 60.0% up from the prior year.
Capital Expenditures reached $14000.0 in Q4 2019 per DMAC's latest filing, up from -$13000.0 in the prior quarter.
In the past five years, Capital Expenditures ranged from a high of $32000.0 in Q1 2018 to a low of -$13000.0 in Q4 2018.